InvestorsHub Logo
icon url

jazzbeerman

10/30/07 11:29 AM

#18273 RE: jazzbeerman #18272

then again....

* In the SINGLE DOSE study, (in former non responders to immunotherapy), half the patients in the 1 mg/kg cohort, and also half the patients in the 3 mg/kg cohort, achieved a half log decrease.




and that was just one single dose of bavi, in former non responders to immunotherapy...

* There was also a patient who got 3 mg and did a 1.5 log decrease.

and again- that was just one single dose of bavi, in former non responders to immunotherapy...


* then, 5 out of 6 patients at the 6 mg dose did a half log, or better




and again- that was just one single dose of bavi, in former non responders to immunotherapy...


---------------------



In the multi-dose study, (and it was only four doses over 2 weeks), half the patients at 3 mg did 1 log.



Maybe less bavi, more doses, over a longer period, will achieve good viral reduction.
PPHM seems to think that once a week for a longer time period is promising.

and I can only assume that they feel this way based on Duke research INTO THE IMMUNE MODULATING MOA.




Maybe a 0.3 mg/kg dose will have impressive results after 8 weekly infusions.
Maybe the optimal dose will still be around 3.0


j
icon url

realist1

10/30/07 12:02 PM

#18274 RE: jazzbeerman #18272

RE "Perhaps we'll simply hear something general saying it was safe in patients treated to date, (it is a safety trial after all), and they've added a new site, etc.

Perhaps they'll mention in general that it's showing signs of efficacy."

In other words, no help for the PPS.
Scratch the HCV/HIV trial off the list of things that might move PP stock.

Monkey paper from Duke (probably will not even list by name PPHM on it) - another nothing.

R&R annual begging for dollars conference - no help there.

Where's that leave shareholders? Hoping for the Gov't contract is about all that's left.